Neermann Joerg
Known title: DirectorCIK: 0001773900
Neermann Joerg's purchase track record
How the stock did after each of Neermann Joerg's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 23, 2022
Stock higher 6 months later
67%
3 months: 100%
Median 6-month return
+27.9%
3 months: +39.0%
Beat the S&P 500
67%
median +25.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/4/2025 | IMUX | $77K | +3.9% | -16.1% | +14.7% |
| 12/13/2022 | IMUX | $103K | +41.9% | +37.1% | +8.7% |
| 11/23/2022 | IMUX | $25K | +39.0% | +27.9% | +2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMUX | ▲ Buy | Open Market | 30,000 | $23K | 6/5/2025 | View on chart |
| IMUX | ▲ Buy | Open Market | 70,000 | $54K | 6/4/2025 | View on chart |
| IMUX | ▲ Buy | Open Market | 47,000 | $59K | 12/14/2022 | View on chart |
| IMUX | ▲ Buy | Open Market | 35,000 | $44K | 12/13/2022 | View on chart |
| IMUX | ▲ Buy | Open Market | 18,000 | $25K | 11/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Immunic Presents Four Abstracts at MSToronto2026
Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.
Immunic Presents Four Abstracts at MSToronto2026. Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.